WO2016012921A3 - Immunogenic polypeptide composed of hla-b7 restricted tumor antigen-derived optimized cryptic peptides, and uses thereof - Google Patents
Immunogenic polypeptide composed of hla-b7 restricted tumor antigen-derived optimized cryptic peptides, and uses thereof Download PDFInfo
- Publication number
- WO2016012921A3 WO2016012921A3 PCT/IB2015/055438 IB2015055438W WO2016012921A3 WO 2016012921 A3 WO2016012921 A3 WO 2016012921A3 IB 2015055438 W IB2015055438 W IB 2015055438W WO 2016012921 A3 WO2016012921 A3 WO 2016012921A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hla
- tumor antigen
- immunogenic polypeptide
- polypeptide composed
- restricted tumor
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 108010091938 HLA-B7 Antigen Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000012737 microarray-based gene expression Methods 0.000 abstract 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15762719.1A EP3193916B1 (en) | 2014-07-22 | 2015-07-17 | Immunogenic polypeptide composed of hla-b7 restricted tumor antigen-derived optimized cryptic peptides, and uses thereof |
JP2017503555A JP6701164B2 (en) | 2014-07-22 | 2015-07-17 | Immunogenic polypeptides composed of optimized latent peptides derived from HLA-B7 restricted tumor antigens and uses thereof |
CA2954964A CA2954964C (en) | 2014-07-22 | 2015-07-17 | Immunogenic polypeptide composed of hla-b7 restricted tumor antigen-derived optimized cryptic peptides, and uses thereof |
CN201580040877.6A CN106661127A (en) | 2014-07-22 | 2015-07-17 | Immunogenic polypeptide composed of HLA-B7 restricted tumor antigen-derived optimized cryptic peptides, and uses thereof |
US15/327,244 US20170157228A1 (en) | 2014-07-22 | 2015-07-17 | Immunogenic Polypeptide Composed of HLA-B7 Restricted Tumor Antigen-Derived Optimized Cryptic Peptides, and Uses Thereof |
ES15762719T ES2765726T3 (en) | 2014-07-22 | 2015-07-17 | Immunogenic polypeptide, consisting of optimized cryptic peptides, derived from the restricted tumor antigen HLA-B7 and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14306187.7 | 2014-07-22 | ||
EP14306187.7A EP2977059A1 (en) | 2014-07-22 | 2014-07-22 | Immunogenic polypeptide composed of HLA-B7 restricted tumor antigen-derived optimized cryptic peptides, and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016012921A2 WO2016012921A2 (en) | 2016-01-28 |
WO2016012921A3 true WO2016012921A3 (en) | 2016-03-31 |
Family
ID=51263344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2015/055438 WO2016012921A2 (en) | 2014-07-22 | 2015-07-17 | Immunogenic polypeptide composed of hla-b7 restricted tumor antigen-derived optimized cryptic peptides, and uses thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US20170157228A1 (en) |
EP (2) | EP2977059A1 (en) |
JP (1) | JP6701164B2 (en) |
CN (1) | CN106661127A (en) |
CA (1) | CA2954964C (en) |
ES (1) | ES2765726T3 (en) |
WO (1) | WO2016012921A2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120142894A1 (en) * | 2009-06-09 | 2012-06-07 | Kostantinos Kosmatopoulos | Identification, Optimization and Use of Shared HLA-B*0702 Epitopes for Immunotherapy |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1795539B1 (en) | 2005-12-06 | 2010-12-01 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
ATE435660T1 (en) * | 2005-12-23 | 2009-07-15 | Vaxon Biotech | IMMUNOGENIC POLYPEPTIDE CONSISTING OF OPTIMIZED CRYPTIC PEPTIDES FROM TUMOR ANTIGENS AND ITS USES |
WO2008010010A1 (en) * | 2006-07-12 | 2008-01-24 | Vaxon Biotech | Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy |
CN102387813B (en) * | 2009-04-02 | 2018-07-31 | 瓦克松生物技术公司 | Identification, optimization and the purposes of hidden HLA-A24 epitopes for immunization therapy |
WO2013150338A1 (en) | 2012-04-04 | 2013-10-10 | Centre National De La Recherche Scientifique | Stapled cell penetrating peptides for intracellular delivery of molecules |
WO2014053882A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
-
2014
- 2014-07-22 EP EP14306187.7A patent/EP2977059A1/en not_active Withdrawn
-
2015
- 2015-07-17 JP JP2017503555A patent/JP6701164B2/en active Active
- 2015-07-17 CN CN201580040877.6A patent/CN106661127A/en active Pending
- 2015-07-17 EP EP15762719.1A patent/EP3193916B1/en active Active
- 2015-07-17 WO PCT/IB2015/055438 patent/WO2016012921A2/en active Application Filing
- 2015-07-17 CA CA2954964A patent/CA2954964C/en active Active
- 2015-07-17 US US15/327,244 patent/US20170157228A1/en not_active Abandoned
- 2015-07-17 ES ES15762719T patent/ES2765726T3/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120142894A1 (en) * | 2009-06-09 | 2012-06-07 | Kostantinos Kosmatopoulos | Identification, Optimization and Use of Shared HLA-B*0702 Epitopes for Immunotherapy |
Non-Patent Citations (1)
Title |
---|
CORNET S ET AL: "Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity", VACCINE, ELSEVIER LTD, GB, vol. 24, no. 12, 15 March 2006 (2006-03-15), pages 2102 - 2109, XP028010542, ISSN: 0264-410X, [retrieved on 20060315], DOI: 10.1016/J.VACCINE.2005.11.015 * |
Also Published As
Publication number | Publication date |
---|---|
EP3193916B1 (en) | 2019-10-16 |
CA2954964C (en) | 2023-11-14 |
CN106661127A (en) | 2017-05-10 |
JP2017526650A (en) | 2017-09-14 |
WO2016012921A2 (en) | 2016-01-28 |
ES2765726T3 (en) | 2020-06-10 |
EP3193916A2 (en) | 2017-07-26 |
CA2954964A1 (en) | 2016-01-28 |
US20170157228A1 (en) | 2017-06-08 |
EP2977059A1 (en) | 2016-01-27 |
JP6701164B2 (en) | 2020-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023002858A (en) | Predicting t cell epitopes useful for vaccination. | |
MX2019006598A (en) | Engineered natural killer cells and uses thereof. | |
GB2573406A (en) | Tumor infiltrating lymphocytes and methods of therapy | |
PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
MX2022005291A (en) | Vaccines for treatment and prevention of cancer. | |
MX2019010972A (en) | High affinity mage-a1-specific tcrs and uses thereof. | |
MX2019012223A (en) | Anti-cd137 antibodies and methods of use thereof. | |
MX2019008413A (en) | Immunoengineered pluripotent cells. | |
MX2015015511A (en) | Predicting immunogenicity of t cell epitopes. | |
WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
PH12016502370A1 (en) | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof | |
MX2016014711A (en) | Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml). | |
MX2019010459A (en) | Peptide vaccines. | |
PH12019502637A1 (en) | Chimeric antigen receptors targeting flt3 | |
WO2016105542A3 (en) | Nanoparticle compositions and methods for immunotherapy | |
NZ732211A (en) | Combination immunotherapy approach for treatment of cancer | |
EP3539979A3 (en) | Personalized immunotherapy against several neuronal and brain tumors | |
TW201613956A (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | |
MA40228A (en) | Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof | |
MX2019009848A (en) | Proteins binding her2, nkg2d and cd16. | |
WO2016073595A8 (en) | T cells and dendritic cells for polyomavirus therapy | |
PH12016501689A1 (en) | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof | |
WO2019030757A8 (en) | Chimeric antigen receptor for her2/neu and t-cells expressing same | |
WO2016011432A3 (en) | Identification of immunogenic mhc class ii peptides for immune-based therapy | |
WO2015149016A3 (en) | Breast and ovarian cancer vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15762719 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2954964 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15327244 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2017503555 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015762719 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015762719 Country of ref document: EP |